Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx has two product candidates in late-stage clinical development: Sulodexide or KRX-101, for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes, and Perifosine or KRX-0401, for the treatment of multiple forms of cancer. Keryx announced that it has acquired ACCESS Oncology, Inc. and its subsidiaries or ACCESS Oncology, a cancer-focused biotechnology company. The acquired drug portfolio includes three clinical stage compounds, designated as KRX-0401, KRX-0402 and KRX-0403.